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 Abstract 
Background: Observational data have described the association of blood pressure (BP) with 
mortality as a “J” shaped i.e. mortality rates increase below a certain BP threshold.  We aimed 
to analyze the associations between BP and prognosis in a population of acute myocardial 
infarction (MI) patients with heart failure (HF) and/or systolic dysfunction. 
Methods: The datasets included in this pooling initiative are derived from four trials: 
CAPRICORN, EPHESUS, OPTIMAAL and VALIANT. A total of 28,771 patients were 
included in this analysis. Arithmetic mean of all office BP values measured throughout follow-
up were used. The primary outcome was cardiovascular death. 
Results: The mean±SD age was 65±11.5 and 30% were female. Patients in the lower systolic 
blood pressure (SBP) quintiles had higher rates of cardiovascular death: adjusted HR 
(95%CI)=2.49 (2.26-2.74) for SBP≤112 mmHg and HR (95%CI)=1.29 (1.16-1.43) for SBP 
between 113 and 120 mmHg (reference: SBP=121 to 128 mmHg). The findings for HF 
hospitalization and MI were similar. However, stroke rates were higher in patients within the 
highest SBP quintile (reference: SBP=121 to 128 mmHg): HR (95%CI)=1.38 (1.11-1.72). 
Patients who died had a much shorter follow-up (0.7 vs. 2.1 years), less BP measurements (4.6 
vs. 9.8) and lower mean BP (-8 mmHg in the last SBP measurement compared to patients who 
remained alive during the follow-up), suggesting that the associations of low BP and increased 
cardiovascular death represent a reverse causality phenomenon. 
Conclusion: SBP values below 125 mmHg were associated with increased cardiovascular death, 
but these findings likely represent a reverse causality phenomenon.  
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Introduction 
Although is undisputable that lowering blood pressure improves outcome of 
hypertensive patients1, the threshold to which blood pressure should be lowered is a matter of 
debate and likely to be population-specific2-4. In addition, several observational studies and 
post-hoc analyses have suggested that lowering blood pressure below a certain threshold may be 
deleterious, as reflected by the so-called J-curve phenomenon5-7. An observational study in 
22,672 “real-life” patients with stable coronary artery disease treated for hypertension, a low 
systolic (<120 mm Hg) and diastolic (<70 mm Hg) blood pressures were associated with an 
increased risk of cardiovascular events, supporting the J-curve phenomenon, and suggesting that 
in patients with coronary artery disease a low blood pressure may be deleterious8.   
Recently the SPRINT trial showed that assigning high cardiovascular risk patients (but 
without diabetes or prior stroke) to an intensive blood pressure (BP) treatment arm with the goal 
of lowering systolic blood pressure (SBP) below 120 mmHg versus a standard treatment arm 
with the goal of lowering SBP below 140 mmHg, improved outcomes in this population, 
notably by reducing the rates of heart failure (HF) hospitalizations and death (both 
cardiovascular and all-cause)9. The SPRINT trial results were also reinforced by a recent meta-
analysis of trials allocating patients in intensive versus standard treatment arms10, although in 
this meta-analysis the mean BP in the intensive therapy group was 133/76 mmHg, compared to 
140/81 mmHg in the standard therapy group. Therefore, a discrepancy exists between data 
derived from randomized trials and data derived from observational studies. One potential 
explanation is that observational data are prone to bias, notably residual confounding and 
reverse causality. This last is particularly relevant, i.e. is not lower blood pressure that causes 
the adverse outcomes, but instead are the “sicker” patients who have lower blood pressure near 
their life-end11.   
The aim of the present manuscript is to study the association between blood pressure 
levels and cardiovascular outcomes in a large cohort of acute myocardial infarction patients 
with systolic dysfunction and/or HF. 
 
Methods 
Study population 
The high-risk MI initiative consists of a previously published cohort of pooled patient 
data derived from four clinical trials12. Briefly, the main objectives of the project are to provide 
a comprehensive and statistically robust analysis of long-term clinical outcomes in high-risk 
survivors of MI. The datasets included in this pooling initiative were: the effect of Carvedilol on 
Outcome after Myocardial Infarction in Patients with Left Ventricular Dysfunction trial 
(CAPRICORN)13, 14, the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy 
and Survival Study (EPHESUS)15, 16, the Optimal Trial in Myocardial Infarction with 
Angiotensin II Antagonist Losartan (OPTIMAAL)17, 18 and the Valsartan in Acute Myocardial 
Infarction trial (VALIANT)19, 20. Full details of total enrolled patients, the inclusion and 
exclusion criteria for each trial, the endpoints as well as the results have previously been 
published12. Each trial enrolled patients with left ventricular systolic dysfunction, HF or both 
between 12 h and 21 days after acute MI.  
The respective chairpersons of the Steering Committees of the four trials initiated the 
pooling project.  
The studies were all conducted in accordance with the Declaration of Helsinki and 
approved by site ethics committees. All participants gave written informed consent to 
participate in the studies. 
Blood pressure measurements 
 In each trial, the investigators measured patients` office blood pressure after a rest of 5 
minutes in the sitting position at each ±4-month interval using an automated electronic 
sphygmomanometer. Three BP measurements were performed at each visit and the mean BP at 
each visit was used in the present study. The main analysis was done with the arithmetic mean 
of all blood pressure values measured throughout follow-up, from the baseline visit to the visit 
before an event or (in patients without an event) up to the last visit. All analyses were done for 
systolic blood pressure and diastolic blood pressure separately (Pearson correlation SBP/DBP 
=0.67). Patients were categorised into five groups (i.e., balanced quintiles) for both systolic and 
diastolic blood pressure. 
Outcomes 
The primary outcome was cardiovascular death. Secondary outcomes were 
hospitalization for heart failure, myocardial infarction, stroke, and all-cause death.  
We only analysed patients with at least one BP measurement before the outcome. 
Endpoints were independently adjudicated in the respective trials. 
Statistical methods 
In descriptive analyses, continuous variables are expressed as mean ± standard deviation 
(SD) as they were normally distributed.  Categorical variables are expressed as frequencies and 
proportions (%).  
The one-way analysis of variance “ANOVA test” was used to compare blood pressure 
across quintiles. Baseline laboratory measurements were obtained at the time of inclusion. The 
estimated glomerular filtration rate was calculated using the CKD-EPI equation21 
Cox proportional hazard regression models were used to model the associations 
between blood pressure and long-term events both in univariable and multivariable analysis. 
Cox model assumptions were verified and blood pressure measurements were analysed as 
quintiles and also converted to restricted cubic splines as association with outcomes was non-
linear. In the multivariable models, the covariates were chosen from demographic (age and 
gender), clinical (body mass index, smoking, hypertension, diabetes, heart failure history, 
previous stroke, previous myocardial infarction, peripheral artery disease, atrial fibrillation and 
heart rate), laboratorial (estimated glomerular filtration rate), and concomitant treatments 
(ACEi/ARBs, beta-blockers, and diuretics). All variables were previously found to be clinically 
relevant and associated with outcomes22. An interaction term between blood pressure measures 
and age was prespecified in the statistical analysis plan and was non-significant for all outcomes 
(p >0.1). No multiple imputation was performed and only variables with <10% of missing 
values were used for adjustment. Left ventricular ejection fraction, glucose, electrolytes and 
hemoglobin were not included for adjustment in the models` due to a high (>75%) percentage of 
missing values. 
Model calibration was assessed visually by plotting the mean of model-predicted 
survival at 2 years in each decile of predicted survival against the observed survival estimated 
by the Kaplan-Meier method as previously described23.  
Statistical analyses were performed using the R software (The R Foundation for 
Statistical Computing). A p value <0.05 was considered statistically significant. 
 
Results 
Baseline characteristics 
 A total of 28,771 patients were included in the present analysis (no patients were 
excluded). The mean ± standard deviation age was 65 ± 11.5 years and 30% were female.  The 
overall mean follow-up was 2.0 ± 1.0 years (2.1 ± 0.8 years in the group of patients who 
remained alive during follow-up vs. 0.7 ± 0.6 years in those who died from CV causes). 
 By quintiles of SBP, patients in the lower quintiles were younger, more often male, 
active smokers, with history previous myocardial infarction, and had lower body mass index, 
lower left ventricular ejection fraction, lower serum sodium levels, higher heart rate and better 
eGFR (all p<0.0001). Table 1. Patients in the lower quintiles of DBP were older, more often 
diabetic, and with worse renal function, but they also had lower ejection fraction, body mass 
index, and serum sodium, were more often smokers, and had previous myocardial infarction 
more often reported, as described for SBP. Supplemental Table 1.  
Mean blood pressure outcome associations 
 Patients in the lower quintiles of SBP had higher rates of cardiovascular death compared 
to patients with a SBP between 121 and 128 mmHg (reference category): adjusted hazard ratio 
(HR), 95% confidence interval (CI) =2.49 (2.26-2.74) for SBP ≤112 mmHg and 1.29 (1.16-
1.43) for SBP between 113 and 120 mmHg. Table 2. Patients in the higher SBP quintile had the 
lower rate of cardiovascular death, adjusted HR (95%CI) =0.76 (0.68-0.85) for SBP >137 
mmHg, compared with the same reference group. Consistent findings were also observed for 
HF hospitalization and myocardial infarction. Table 2. Regarding stroke, patients in the higher 
and lower mean SBP quintile had a higher stroke risk: HR (95%CI) =1.38 (1.11-1.72) and 1.66 
(1.32-2.10), respectively (compared with the reference group of SBP between 121 and 128 
mmHg). Table 2. Patients in the lowest quintiles of DBP also presented increased risk of 
cardiovascular death, adjusted HR (95%CI) =1.88 (1.70-2.07) for DBP ≤68 mmHg and HR 
(95%CI) =1.23 (1.10-1.36) for DBP of 69 to 72 mmHg. High DBP was also independently 
associated with increased stroke rate, HR (95%CI) =1.41 (1.13-1.75). Supplemental Table 2. 
Sensitivity analysis excluding patients with diabetes, stroke history and eGFR <45 
ml/min/1.73m2 and additional adjustment for each trial and oral anticoagulant use, provided 
similar results to those observed in the whole population. Supplemental Table 3 & 4. 
Restricted cubic spline graphical representations of the relationship between BP and the 
outcomes of interest are depicted in Figure 1.  
Blood pressure analysis and comparison of patients with and without events 
 Compared to those who were alive, patients who died from cardiovascular causes 
during the follow-up had similar absolute BP values at baseline (i.e. randomization): 121/72 
mmHg (alive) vs. 122/72 mmHg (dead), but lower BP before the fatal event: 129/76 mmHg 
(alive) vs. 121/72 (dead); absolute difference in SBP = +1 mmHg in those who died at baseline 
vs. -8 mmHg in those who died in the last available recording. Patients who died from 
cardiovascular causes also had fewer BP measurements during the follow-up (5 vs. 10 
measures) and a much shorter mean follow-up (0.7 vs. 2.1 years). Consistently, in the patients 
who died during follow-up, the mean BP was lower than in patients who remained alive. Table 
3. Patients with non-fatal events (HFH, MI, stroke) also had fewer BP measurements (≈4 vs. 9) 
and a much shorter follow-up (0.7 vs. 1.9 years) compared to patients with fatal events. Patients 
with HFH and MI also presented lower last BP values compared to patients who did not have 
these events (128/76 vs. 123/73 for HFH and 128/76 vs. 125/73 for MI). On the other hand, 
patients who had a stroke had higher last BP values compared to patients without stroke events 
(127/75 vs. 129/76). Supplemental Table 5. The associations between baseline (i.e. 
randomization) BP values and last (i.e. before cardiovascular death or last available if alive) BP 
values are represented graphically in the Supplemental Figures 1 to 5.   
 
Discussion 
The results of the present study in a specific population of patients with systolic 
dysfunction or overt HF after MI, show that blood pressure levels below 125/75 mmHg are 
associated with worse outcomes. The so-called J-shaped phenomenon (i.e. a higher 
cardiovascular risk below a certain BP threshold) was also observed in this large dataset. 
However, we found that patients with a fatal event had fewer BP measurements and lower last 
BP values compared to patients who remained alive during follow-up. Therefore, their mean BP 
approached the end-life values, suggesting a reverse causation as explanation for these findings.  
 In our study patients with lower mean BP were also those with higher heart rate, lower 
body mass index (BMI), with higher proportion of previous MI, and current smoking. All these 
variables have been associated to worse outcomes in patients with HF and/or MI24-27 and are 
likely to carry residual confounding, accounting, in part, for the reported associations. In the 
present manuscript, after adjusting for potential confounders, having a low systolic (<125 
mmHg) and diastolic (<75 mmHg) BP was associated with non-fatal cardiovascular events (MI, 
stroke, HF hospitalization) and also death (both cardiovascular and from all-causes). 
Overlapping results were observed in a subpopulation with less co-morbidities (i.e., no diabetes, 
no previous history of stroke and with eGFR >45 ml/min/1.73m2). Interestingly, in this 
population having high SBP (>140 mmHg) was only independently associated with a higher 
risk of stroke (but not CV death, MI or HF hospitalization). Patients who had a stroke were the 
only population with a non-fatal event that had higher blood pressure values before the event. 
These findings (positive association of low BP with all CV events and high BP only with 
stroke) may support the theoretical notion that patients with CAD may require higher BP levels 
to maintain coronary perfusion8. However, in SPRINT9, the intensive treatment benefit was 
present regardless of the presence of previous cardiovascular disease (p for interaction =0.39) 
and the attained mean BP levels in the intensive treatment group were 121.4/68.7 mmHg vs. 
136.2/76.3 mmHg in the standard treatment group. The ACCORD2 trial enrolled diabetic 
patients at high cardiovascular risk and also targeted SBP of less than 120 mmHg. However, in 
the ACCORD trial intensive treatment did not reduce the primary composite outcome of 
nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes, but it 
reduced the prespecified secondary outcome of annual rates of stroke (although the ACCORD 
trial might have been underpowered to detect between group differences for the primary 
outcome as it had half of the sample size of SPRINT and did not incorporate HF 
hospitalizations in the primary outcome). In the HOPE-3 trial, blood pressure lowering in 
intermediate risk persons without cardiovascular disease also did not reduce the coprimary 
composite outcome of CV death, MI or stroke, but the prespecified subgroup of patients with 
baseline SBP >143.5 mmHg seemed to benefit from anti-hypertensive therapy28. Despite 
patients included in the HOPE-3 trial represent a completely different setting from those studied 
herein, no event rate increase was observed in patients with lower baseline BP. On the other 
hand, in observational studies the association with adverse prognosis steeply increases with BP 
levels below 125/75 mmHg (like in the present study)4, 5, 8, 29, however (in addition to potential 
residual confounding bias, as above referred) one should account for reverse causation bias. In a 
post-hoc analysis derived from the ONTARGET and TRANSCEND trials29 - that tested the 
efficacy and safety of ARBs on high CV risk populations - the authors found a “J-shaped 
association” of SBP and DBP with CV death, MI, and HF (but not stroke). Nonetheless, the 
authors also state that they cannot rule out a reverse causality effect on their findings, as 
multiple co-morbidities may cause BP decrease and are associated with higher morbidity and 
mortality rates during the trial. The present analysis, demonstrates that patients who died had 
lower BP values compared to those who remained alive during follow-up (despite similar mean 
BP values at baseline). A recent population-based study also showed a lower mean BP values in 
patients who died, suggesting that nonrandomized epidemiological associations of low SBP 
with higher mortality may be due to reverse causation, because participants with lower blood 
pressure values are closer, on average, to the end of life30. These findings suggest that a reverse 
causation bias is likely to drive the present associations as patients approaching death have 
lower BP values, which may be due to poor health conditions (e.g. “pump” failure, systemic 
inflammation, renal disease) and deteriorating nutritional status toward the end of life31, 32. 
Therefore, one should be very cautious in mixing apples and oranges, as data from randomized 
controlled trials (RCTs) provide much stronger evidence than observational or retrospective 
analysis. Hence, the findings reported herein (and in other observational data) may simply 
represent associations between “sicker” populations and increased adverse outcomes, and any 
causality inference should be strongly discouraged. 
Previous observational studies have yielded conflicting results for the risk of stroke, in 
which the “J-shaped phenomenon” has not been consistently observed8, 29, 33, 34. However, stroke 
was a less frequent outcome in most analyses which, as a result, meant that many lacked 
statistical power to assess the relationship between BP and stroke. Moreover, in SPRINT the 
rates of stroke were not reduced by intensive BP lowering9, but it should be acknowledged that 
stroke was a component of the primary outcome (and not the primary outcome on which sample 
size calculations were based), hence this trial was also underpowered to assess the effect of 
intensive BP lowering on stroke. Our study-population had more than 900 adjudicated stroke 
events (almost twice the total primary outcome events reported in SPRINT) and allows the 
study of the association between BP levels and stroke risk in an adequately powered fashion, 
and show that both higher and lower BP are associated with higher stroke rates, suggesting a “J-
shaped phenomenon” in this population.  
The data presented herein are the first to describe the association of mean BP with 
several CV outcomes in a large population of MI patients with systolic dysfunction and/or heart 
failure. Importantly, these findings suggest that the association between low BP levels and 
worse CV outcomes may be driven by a reverse causation phenomenon (as also suggested from 
population-based studies30), hence caution is warranted when interpreting associations between 
BP and outcomes in observational data. 
 
Limitations 
Several limitations of this study should be acknowledged: 1) this is a post-hoc analysis 
of “high-risk” acute MI trial-populations in which hypertension history (although more than half 
of the patients were hypertensive) was not an entry criteria, hence the results presented herein 
cannot be extrapolated to other populations; 2) the retrospective nature of these results makes 
them prone to confounding and causality cannot be presumed nor even suggested; 3) despite 
extensive adjustment, many unmeasured variables could account for residual confounding bias; 
4) the lower BP values observed near the end of life, and the lower mean BP described in 
patients who died from cardiovascular causes suggests a reverse causation phenomenon as 
responsible for the associations of low blood pressure with cardiovascular death, however this 
phenomenon should be highlighted and data from RCT should be preferred to observational 
associations; 5) patients with CV events also had a shorter follow-up which may have 
contributed for reverse causation to have influenced the associations described in the present 
manuscript; 6) BP measurements were made at the office in trial visits and did not use 
standardized techniques across trial and centres, however given the great number of patients and 
measures the occurrence of systematic error is unlikely; 7) clinical variables and outcome events 
were ascertained in each trial by the study investigators and independent adjudication 
committees, respectively. Errors in clinical records and event adjudication might have occurred, 
however these are also unlikely to be systematic and influence the associations presented herein 
in a systematic fashion; 8) medication doses or changes during follow-up are not available in the 
dataset, therefore we cannot ascertain which patients had treatment intensification during the 
trial; 9) biomarkers (e.g. NT-proBNP and Troponins) could help in better stratifying patients` 
risk, however biomarker data were not available in the dataset; 10) the datasets were transferred 
by the sponsors with no information on treatment allocation, hence the possible influence of the 
treatment allocation on blood pressure and outcomes cannot be assessed in the present study. 
 
Conclusions 
The results of the present study in a selected population of myocardial infarction 
patients with systolic dysfunction or heart failure, show that blood pressure values below 125/75 
mmHg were associated with worse cardiovascular outcomes. Patients with a fatal event had 
fewer BP measurements and lower mean BP near the deadly event. Therefore, their mean BP 
was lower, suggesting that a reverse causation phenomenon accounts for the associations of low 
BP and CV death in this setting.  
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Table 1. Demographic and baseline characteristics of the patients, for the total population and for systolic blood pressure quintiles 
Population characteristics N. All population 
SBP Q1 
≤112 mmHg 
SBP Q2 
113 to 120 mmHg 
SBP Q3 
121 to 128 mmHg 
SBP Q4 
129 to 137 mmHg 
SBP Q5 
>137 mmHg p-value 
Age (years) 28771 65.0 ± 11.5 61.2 ± 12.3 63.0 ± 11.9 64.7 ± 11.2 66.6 ± 10.4 68.6 ± 9.7 <0.0001 
Female gender 28771 8582 (29.8 %) 1249 (22.6 %) 1315 (23.1 %) 1451 (27.0 %) 1775 (32.0 %) 2388 (43.3 %) <0.0001 
Heart rate (bpm) 28691 75.7 ± 12.8 77.3 ± 13.2 75.9 ± 12.7 75.3 ± 12.5 74.9 ± 12.2 74.3 ± 12.5 <0.0001 
Mean SBP (mmHg) 27644 124.9 ± 14.9 105.4 ± 5.3 116.4 ± 2.3 123.9 ± 2.2 132.1 ± 2.7 146.9 ± 8.6 <0.0001 
Mean DBP (mmHg) 27644 74.3 ± 8.0 66.5 ± 5.7 71.6 ± 5.5 74.5 ± 5.7 77.3 ± 6.2 81.7 ± 7.4 <0.0001 
N. BP measures 28771 8.4 ± 3.7 7.8 ± 3.7 8.7 ± 3.4 9.1 ± 3.2 9.1 ± 3.1 9.2 ± 3.2 <0.0001 
BMI (Kg/m2) 28098 27.5 ± 4.8 26.8 ± 5.1 27.2 ± 4.6 27.6 ± 4.7 27.8 ± 4.7 28.1 ± 4.9 <0.0001 
LVEF (%) 19903 34.3 ± 8.9 32.3 ± 8.8 34.0 ± 8.6 34.8 ± 8.6 35.2 ± 8.3 36.1 ± 9.3 <0.0001 
eGFR (ml/min/1.73m2) 27703 70.2 ± 36.8 74.6 ± 51.9 72.6 ± 29.9 71.3 ± 29.4 68.5 ± 32.3 65.6 ± 37.2 <0.0001 
Hemoglobin (g/L) 12862 133.5 ± 16.0 132.0 ± 16.5 134.3 ± 16.0 134.2 ± 15.8 134.1 ± 15.9 133.0 ± 15.7 <0.0001 
Sodium (mmol/L) 13177 139.4 ± 3.8 138.5 ± 3.8 139.1 ± 3.6 139.4 ± 3.6 139.7 ± 4.2 140.0 ± 3.5 <0.0001 
Potassium (mmol/L) 13115 4.2 ± 0.5 4.2 ± 0.5 4.3 ± 0.5 4.3 ± 0.5 4.3 ± 0.4 4.2 ± 0.5 0.001 
Glucose (mmol/L) 13088 7.4 ± 3.4 7.4 ± 3.7 7.3 ± 3.3 7.4 ± 3.6 7.4 ± 3.2 7.6 ± 3.3 0.015 
Current smoker, n. (%) 28735 9051 (31.5 %) 1768 (32.0 %) 1817 (32.0 %) 1686 (31.4%) 1730 (31.3%) 1654 (30.1%) <0.0001 
Previous MI, n. (%) 28769 7490 (26.0 %) 1481 (26.8 %) 1492 (26.2 %) 1324 (24.6 %) 1406 (25.4 %) 1372 (24.9 %) 0.049 
Atrial fibrillation, n. (%) 28771 3754 (13.0 %) 672 (12.1 %) 683 (12.0 %) 620 (11.5 %) 742 (13.4 %) 784 (14.2 %) <0.0001 
HF history, n. (%) 28771 11181 (38.9 %) 2138 (38.7 %) 2089 (36.7 %) 1893 (35.2 %) 2014 (36.4 %) 2233 (40.5 %) <0.0001 
Peripheral artery disease, n. (%) 28769 2357 (8.2 %) 363 (6.6 %) 428 (7.5 %) 407 (7.6 %) 506 (9.1 %) 526 (9.5 %) <0.0001 
Hypertension history, n. (%) 28771 15570 (54.1 %) 1813 (32.8 %) 2369 (41.7 %) 2859 (53.2 %) 3583 (64.7 %) 4225 (76.7 %) <0.0001 
Diabetes history, n. (%) 28771 7386 (25.7 %) 1131 (20.4 %) 1225 (21.5 %) 1381 (25.7 %) 1561 (28.2 %) 1726 (31.3 %) <0.0001 
Previous stroke, n. (%) 28771 2264 (7.9 %) 353 (6.4 %) 389 (6.8 %) 373 (6.9 %) 470 (8.5 %) 542 (9.8 %) <0.0001 
ACEi, n. (%) 23287 12935 (55.5 %) 2698 (56.4 %) 2598 (55.8 %) 2382 (55.7 %) 2461 (57.0 %) 2366 (57.2 %) 0.54 
ARB, n. (%) 23287 346 (1.5 %) 62 (1.3 %) 55 (1.2 %) 72 (1.7 %) 62 (1.4 %) 77 (1.9 %) 0.053 
Beta-blockers, n. (%) 26802 17824 (66.5 %) 3497 (68.9 %) 3560 (67.5 %) 3392 (67.7 %) 3392 (65.9 %) 3330 (64.4 %) <0.0001 
Diuretics, n. (%) 28761 13013 (45.2 %) 2515 (45.5 %) 2422 (42.6 %) 2251 (41.9 %) 2473 (44.7 %) 2587 (47.0 %) <0.0001 
CVM, n. (%) 28742 4380 (15.2 %) 1328 (23.1 %) 927 (15.2 %) 675 (12.4 %) 717 (12.6 %) 733 (12.8 %) <0.0001 
HF hospitalization, n. (%) 28742 3385 (11.8 %) 845 (15.3 %) 666 (11.7 %) 544 (10.1 %) 589 (10.6 %) 630 (11.4 %) <0.0001 
MI, n. (%) 28742 3112 (10.8 %) 781 (13.6 %) 657 (10.8 %) 491 (9.0 %) 542 (9.5 %) 641 (11.2 %) <0.0001 
Stroke, n. (%) 28742 931 (3.2 %) 181 (3.1 %) 172 (2.8 %) 142 (2.6 %) 182 (3.2 %) 254 (4.4 %) <0.0001 
All-cause death, n. (%) 28742 5103 (17.8 %) 1500 (26.1 %) 1095 (17.9 %) 789 (14.5 %) 836 (14.7 %) 883 (15.4 %) <0.0001 
Legend: SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; LVEF, left ventricular ejection fraction; estimated glomerular 
filtration rate by CKD-EPI formula; HF, heart failure; ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; CVM, 
cardiovascular mortality; MI, myocardial infarction.
 
Table 2. Crude and adjusted hazard ratios for quintiles of systolic blood pressure 
Blood pressure quintiles Crude HR (95%CI) P-value Adjusted* HR (95%CI) P-value 
Cardiovascular death 
Systolic blood pressure 
≤112 mmHg 2.128 (1.942-2.332) <0.0001 2.486 (2.257-2.739) <0.0001 
113 to 120 mmHg 1.203 (1.089-1.329) <0.0001 1.291 (1.164-1.432) <0.0001 
121 to 128 mmHg 1 - 1 - 
129 to 137 mmHg 0.998 (0.899-1.107) 0.96 0.893 (0.801-0.996) 0.041 
>137 mmHg 0.958 (0.863-1.064) 0.42 0.760 (0.681-0.847) <0.0001 
Heart failure hospitalization 
Systolic blood pressure 
≤112 mmHg 2.117 (1.884-2.378) <0.0001 2.663 (2.355-3.011) <0.0001 
113 to 120 mmHg 1.321 (1.167-1.495) <0.0001 1.497 (1.317-1.703) <0.0001 
121 to 128 mmHg 1 - 1 - 
129 to 137 mmHg 1.037 (0.910-1.181) 0.59 0.935 (0.817-1.070) 0.33 
>137 mmHg 1.238 (1.093-1.403) 0.001 0.934 (0.819-1.065) 0.31 
Myocardial infarction 
Systolic blood pressure 
≤112 mmHg 1.706 (1.525-1.91) <0.0001 1.953 (1.735-2.198) <0.0001 
113 to 120 mmHg 1.225 (1.09-1.376) 0.001 1.284 (1.137-1.45) <0.0001 
121 to 128 mmHg 1 - 1 - 
129 to 137 mmHg 1.040 (0.92-1.174) 0.53 0.958 (0.845-1.087) 0.51 
>137 mmHg 1.208 (1.075-1.359) 0.002 1.034 (0.915-1.169) 0.59 
Stroke 
Systolic blood pressure 
≤112 mmHg 1.424 (1.142-1.776) 0.002 1.661 (1.317-2.095) <0.0001 
113 to 120 mmHg 1.135 (0.907-1.419) 0.27 1.234 (0.979-1.556) 0.074 
121 to 128 mmHg 1 - 1 - 
129 to 137 mmHg 1.271 (1.02-1.582) 0.032 1.165 (0.928-1.461) 0.18 
>137 mmHg 1.684 (1.371-2.07) <0.0001 1.381 (1.113-1.715) 0.003 
All-cause death 
Systolic blood pressure 
≤112 mmHg 2.054 (1.887-2.237) <0.0001 2.410 (2.203-2.637) <0.0001 
113 to 120 mmHg 1.216 (1.109-1.332) <0.0001 1.314 (1.195-1.446) <0.0001 
121 to 128 mmHg 1 - 1 - 
129 to 137 mmHg 0.982 (0.892-1.082) 0.72 0.888 (0.803-0.982) 0.021 
>137 mmHg 0.989 (0.899-1.089) 0.83 0.792 (0.717-0.876) <0.0001 
Models adjusted for age, gender, body mass index, estimated glomerular filtration rate, smoking status, history of hypertension, diabetes, heart failure history, 
previous myocardial infarction, previous stroke, peripheral artery disease, atrial fibrillation, heart rate, ACEi/ARB, beta-blockers, and diuretics (not adjusted 
for hemoglobin, glucose, electrolytes or left ventricular ejection fraction due to high % of missing values). 
P for interaction with Age for SBP =0.53 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Patient characteristics and blood pressure analysis according to the primary outcome 
event 
 
Alive 
(n=24371 
CV death 
(n=4400) p-value 
Age (years) 64.0 ± 11.3 70.3 ± 10.7 <0.0001 
Female, n (%) 6966 (28.6 %) 1616 (36.7 %) <0.0001 
Heart rate (bpm) 75.2 ± 12.5 78.9 ± 13.8 <0.0001 
Current smoker, n (%) 8691 (35.7 %) 1809 (41.2 %) <0.0001 
Body mass index (kg/m2) 27.6 ± 4.8 27.1 ± 4.9 <0.0001 
eGFR (ml/min/1.73m2) 71.8 ± 38.0 61.4 ± 27.7 <0.0001 
Myocardial infarction, n (%) 5687 (23.3 %) 1803 (41.0 %) <0.0001 
Atrial fibrillation, n (%) 2781 (11.4 %) 973 (22.1 %) <0.0001 
Heart failure, n (%) 8809 (36.1 %) 2372 (53.9 %) <0.0001 
Peripheral vascular disease, n (%) 1790 (7.3 %) 567 (12.9 %) <0.0001 
Hypertension, n (%) 12881 (52.9 %) 2689 (61.1 %) <0.0001 
Diabetes, n (%) 5861 (24.0 %) 1525 (34.7 %) <0.0001 
Stroke, n (%) 1689 (6.9 %) 575 (13.1 %) <0.0001 
Mean SBP (mmHg) 125.3 ± 14.6 121.4 ± 16.0 <0.0001 
Mean DBP (mmHg) 74.6 ± 7.7 71.8 ± 9.4 <0.0001 
Baseline SBP (mmHg) 120.8 ± 16.6 121.8 ± 17.6 0.0002 
Baseline DBP (mmHg) 71.7 ± 10.7 71.6 ± 11.5 0.45 
Last SBP (mmHg) 128.5 ± 19.7 120.5 ± 21.3 <0.0001 
Last DBP (mmHg) 76.0 ± 10.9 71.7 ± 12.5 <0.0001 
Number of SBP measures 9.8 ± 2.8 4.6 ± 2.7 <0.0001 
Number of DBP measures 9.8 ± 2.8 4.6 ± 2.7 <0.0001 
Follow-up (years) 2.1 ± 0.8 0.7 ± 0.6 <0.0001 
Legend: eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure, DBP, 
diastolic blood pressure. 
  
 
 
 
 
 
 
 
 
 
 
Figure 1. Adjusted associations between mean blood pressure and the studied outcomes 
 
Legend: SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, hazard ratio; CI, 
confidence interval. 
All models are adjusted for age, gender, body mass index, estimated glomerular filtration rate, 
smoking status, history of hypertension, diabetes, heart failure history, previous myocardial 
infarction, previous stroke, peripheral artery disease, atrial fibrillation and heart rate. 
